Oncoinvent ASA ("Oncoinvent" or the "Company") has today granted 3,560,000 share
options under its long term share incentive scheme for employees (the "Option
Program"), each with a strike price of NOK 2.4991 of these 2,210,000 share
options were granted to primary insiders of the Company. For more information
about the grant of share options to primary insiders, see the attached forms.
Following today's grant, a total of 4,789,808 share options have been granted
under the Option Program.
This information is subject to the disclosure requirements pursuant to article
19 of the regulation EU 596/2014 (the EU Market Abise Regulation) and section
5-12 of the Norwegian Securities Trading Act.
About Oncoinvent
Oncoinvent ASA is a clinical stage, radiopharmaceutical company developing
innovative treatments for solid cancers. The technology platform is focused on
the use of alpha-emitting radionuclides to deliver powerful radiation directly
to cancer cells. The Company's lead product candidate, Radspherin®, is being
advanced through clinical development by a team with experience from all stages
of radiopharmaceutical development. Internal manufacturing and supply chain
capabilities have been established, which now have the capacity to supply
Radspherin® for multi-center phase 2 clinical studies.
For further information, please contact:
Øystein Soug, Chief Executive Officer
Email: soug@oncoinvent.com
Tore Kvam, Chief Financial Officer
Email: kvam@oncoinvent.com